Trends in Mortality Due to Myocardial Infarction, Stroke, and Pulmonary Embolism in Patients Receiving Dialysis

This cohort study assesses the mortality rates caused by myocardial infarction, stroke, and pulmonary embolism in a large cohort of European patients receiving dialysis.

[1]  C. Zoccali,et al.  Data from the ERA-EDTA Registry was examined for trends in excess mortality in European adults on kidney replacement therapy. , 2020, Kidney international.

[2]  D. Cutler,et al.  Trends and Racial Differences in First Hospitalization for Stroke and 30-Day Mortality in the US Medicare Population From 1988 to 2013 , 2019, Medical care.

[3]  S. Normand,et al.  Twenty-Year Trends in Outcomes for Older Adults With Acute Myocardial Infarction in the United States , 2019, JAMA network open.

[4]  Z. Massy,et al.  Changes in co-morbidity pattern in patients starting renal replacement therapy in Europe—data from the ERA-EDTA Registry , 2018, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[5]  M. Alkhouli,et al.  Temporal Trends in the Outcomes of Dialysis Patients Admitted With Acute Ischemic Stroke , 2018, Journal of the American Heart Association.

[6]  Y. Béjot,et al.  National Trends in Patients Hospitalized for Stroke and Stroke Mortality in France, 2008 to 2014 , 2017, Stroke.

[7]  D. De Bacquer,et al.  Vitamin K antagonists for stroke prevention in hemodialysis patients with atrial fibrillation: A systematic review and meta‐analysis , 2017, American heart journal.

[8]  R. Yusen,et al.  Trends in the Management and Outcomes of Acute Pulmonary Embolism: Analysis From the RIETE Registry. , 2016, Journal of the American College of Cardiology.

[9]  F. Pomero,et al.  Time trends and case fatality rate of in-hospital treated pulmonary embolism during 11 years of observation in Northwestern Italy , 2015, Thrombosis and Haemostasis.

[10]  H. Krumholz,et al.  National Trends in Pulmonary Embolism Hospitalization Rates and Outcomes for Adults Aged ≥65 Years in the United States (1999 to 2010). , 2015, The American journal of cardiology.

[11]  C. Herzog,et al.  Trends in Mortality Following Acute Myocardial Infarction Among Dialysis Patients in the United States Over 15 Years , 2015, Journal of the American Heart Association.

[12]  Veikko Salomaa,et al.  Twenty-five-year trends in myocardial infarction attack and mortality rates, and case-fatality, in six European populations , 2015, Heart.

[13]  C. Fuhrman,et al.  Time trends in pulmonary embolism mortality in France, 2000-2010. , 2015, Thrombosis research.

[14]  D. Cutler,et al.  Trends in stroke rates, risk, and outcomes in the United States, 1988 to 2008. , 2014, The American journal of medicine.

[15]  J. Tu,et al.  Warfarin Use and the Risk for Stroke and Bleeding in Patients With Atrial Fibrillation Undergoing Dialysis , 2014, Circulation.

[16]  M. Allon.  Evidence-based cardiology in hemodialysis patients. , 2013, Journal of the American Society of Nephrology : JASN.

[17]  J. Deckers,et al.  Decline in 20-year mortality after myocardial infarction in patients with chronic kidney disease: evolution from the prethrombolysis to the percutaneous coronary intervention era. , 2013, Kidney international.

[18]  R. L. Rushworth,et al.  Trends in pulmonary embolism morbidity and mortality in Australia. , 2013, Thrombosis research.

[19]  G. Raskob,et al.  Apixaban for extended treatment of venous thromboembolism. , 2013, The New England journal of medicine.

[20]  C. Wanner,et al.  Mortality due to pulmonary embolism, myocardial infarction, and stroke among incident dialysis patients , 2012, Journal of thrombosis and haemostasis : JTH.

[21]  C. Clase,et al.  Systematic review and meta-analysis of incidence, prevalence and outcomes of atrial fibrillation in patients on dialysis. , 2012, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[22]  G. Raskob,et al.  Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. , 2012, The New England journal of medicine.

[23]  A. Webster,et al.  Effects of Antiplatelet Therapy on Mortality and Cardiovascular and Bleeding Outcomes in Persons With Chronic Kidney Disease , 2012, Annals of Internal Medicine.

[24]  F. Dekker,et al.  Venous and arterial thrombosis in dialysis patients , 2011, Thrombosis and Haemostasis.

[25]  D. Atar,et al.  Apixaban versus warfarin in patients with atrial fibrillation. , 2011, The New England journal of medicine.

[26]  G. Breithardt,et al.  Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. , 2011, The New England journal of medicine.

[27]  A. Algra,et al.  Excess Mortality and Cardiovascular Events in Patients Surviving Subarachnoid Hemorrhage: A Nationwide Study in Sweden , 2011, Stroke.

[28]  S. Goldhaber,et al.  Dabigatran versus warfarin in the treatment of acute venous thromboembolism. , 2009, The New England journal of medicine.

[29]  S. Yusuf,et al.  Dabigatran versus warfarin in patients with atrial fibrillation. , 2009, The New England journal of medicine.

[30]  Claes Held,et al.  Ticagrelor versus clopidogrel in patients with acute coronary syndromes. , 2009, The New England journal of medicine.

[31]  N. Powe,et al.  Cerebrovascular disease incidence, characteristics, and outcomes in patients initiating dialysis: the choices for healthy outcomes in caring for ESRD (CHOICE) study. , 2009, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[32]  Gert Mayer,et al.  Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. , 2009, The New England journal of medicine.

[33]  Vivian Gu,et al.  Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. , 2008, The New England journal of medicine.

[34]  E. Antman,et al.  Prasugrel versus clopidogrel in patients with acute coronary syndromes. , 2007, The New England journal of medicine.

[35]  Pamela K Woodard,et al.  Multidetector computed tomography for acute pulmonary embolism. , 2006, The New England journal of medicine.

[36]  A. Algra,et al.  Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial , 2006, The Lancet.

[37]  G. Beck,et al.  Cerebrovascular disease in maintenance hemodialysis patients: results of the HEMO Study. , 2006, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[38]  W. März,et al.  Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. , 2005, The New England journal of medicine.

[39]  L. Bressollette.  Eight-Year Follow-Up of Patients With Permanent Vena Cava Filters in the Prevention of Pulmonary Embolism: The PREPIC (Prévention du Risque d’Embolie Pulmonaire par Interruption Cave) Randomized Study , 2005, Circulation.

[40]  Eric Fain,et al.  Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. , 2004, The New England journal of medicine.

[41]  M. Rocco,et al.  Cardiac diseases in maintenance hemodialysis patients: results of the HEMO Study. , 2004, Kidney international.

[42]  Allen J. Taylor,et al.  Incident acute coronary syndromes in chronic dialysis patients in the United States. , 2002, Kidney international.

[43]  D. DeMets,et al.  Effect of Carvedilol on the Morbidity of Patients With Severe Chronic Heart Failure: Results of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study , 2002, Circulation.

[44]  AndrewJ. S. Coats.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial , 2002, The Lancet.

[45]  Salim Yusuf,et al.  Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study , 2001, The Lancet.

[46]  R Cornet,et al.  Renal replacement therapy in Europe: the results of a collaborative effort by the ERA-EDTA registry and six national or regional registries. , 2001, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[47]  Michael F. Oliver,et al.  Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. The MIRACL study. , 2001, Indian heart journal.

[48]  F. Dekker,et al.  The European Registry: Where do We Stand? , 2000, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

[49]  E. Feuer,et al.  Permutation tests for joinpoint regression with applications to cancer rates. , 2000, Statistics in medicine.

[50]  A. Turpie,et al.  A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. , 1999, The New England journal of medicine.

[51]  D. Sackett,et al.  Benefit of carotid endarterectomy in patients with symptomatic moderate or severe stenosis. North American Symptomatic Carotid Endarterectomy Trial Collaborators. , 1998, The New England journal of medicine.

[52]  E. J. Brown,et al.  Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. , 1992, The New England journal of medicine.

[53]  Palle Petersen,et al.  PLACEBO-CONTROLLED, RANDOMISED TRIAL OF WARFARIN AND ASPIRIN FOR PREVENTION OF THROMBOEMBOLIC COMPLICATIONS IN CHRONIC ATRIAL FIBRILLATION The Copenhagen AFASAK Study , 1989, The Lancet.